tickrz reports
tickrz rank
C
Hologic Inc (HOLX)
Healthcare | Health Services
37.35  -0.98%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankC / 230Warren Buffett RankB / 134
Pure Value RankB / 164Dividend RankD / NO DIVIDEND
Moat RankC / 340Financial Strength RankC / 268
Growth RankB / 199Momentum RankC / 349
HOLX vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
HOLXSECTORS&P 500
P/E RATIO14.1832.119.28
EV/EBITDA RATIO7.051711.77
P/S RATIO3.643.62.03
P/B RATIO3.795.53.09
QUALITY
RETURN ON EQUITY31.17%15.64%13.82%
RETURN ON CAPITAL16.13%50.61%10.04%
NET MARGIN11.68%8.18%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
9 OUT OF 9
DEBT-TO-EQUITY113%
INTEREST COVERAGE3.6x
CURRENT RATIO0.85
GROWTH
5 YR EPS GROWTH14.48%
5 YR SPS GROWTH9.62%
5 YR BPS GROWTH-7.18%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank C / 230
Hologic Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking B / 164Warren Buffett ranking B / 134
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Hologic Inc's valuation score is comprised of a P/E ratio of 14.2x, a P/B ratio of 3.8x, a P/S ratio of 3.6x, and an EV/EBITDA ratio of 7.1x. Hologic Inc ranks 164 out of the S&P 500 constituents on valuation--a relatively average score.Hologic Inc ranks 134 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Hologic Inc is probably not for you.

quality
moat C / 340financial strength C / 268
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Hologic Inc has a Piotroski F Score of 9 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 3.6x, a debt/equity ratio of 113% and a Moat Rank of 340 translate to a weak Financial Strength score.


momentum C / 349
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 1.17% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 349. Based on its 12 month stock performance, Hologic Inc will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Hologic Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth B / 199
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 14.5% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -7.2% combine to produce this average score.

Hologic Inc (HOLX)
Healthcare | Health Services
37.35  -0.98%


tickrz rank
C
VALUATION RATIOS
P/E Ratio14.18x
P/B Ratio3.79x
P/S Ratio3.64x
EV/EBITDA Ratio7.05x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
9 OUT OF 9
DEBT-TO-EQUITY113%
INTEREST COVERAGE3.6x
CURRENT RATIO0.85
MOAT
ROE31.17%
ROIC16.13%
Net Margin11.68%
GROWTH
5 YR EPS GROWTH14.48%
5 YR SPS GROWTH9.62%
5 YR BPS GROWTH-7.18%

TICKRZ RANK
Hologic Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Hologic Inc's valuation score is comprised of a P/E ratio of 14.2x, a P/B ratio of 3.8x, a P/S ratio of 3.6x, and an EV/EBITDA ratio of 7.1x. Hologic Inc ranks 164 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Hologic Inc ranks 134 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Hologic Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Hologic Inc has a Piotroski F Score of 9 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 3.6x, a debt/equity ratio of 113% and a Moat Rank of 340 translate to a weak Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 1.17% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 349. Based on its 12 month stock performance, Hologic Inc will not appeal to momentum investors.

VALUE + YIELD
Hologic Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 14.5% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -7.2% combine to produce this average score.